Abstract:Background Sodium-Glucose coTransporter 2 inhibitors (SGLT2i) medication is FDA approved for first-line guideline-directed medical therapy for the treatment of heart failure irrespective of diabetic status. Common examples of SGLT2i used include Empagliflozin and Dapagliflozin and the contraindications of these are GFR<30 with dapagliflozin, <20 with empagliflozin, type 1 diabetics, and lower SBP <95 to 100 mm Hg. The objective of our study is to determine if an inpatient cardiology consult and follow-up with a cardiologist outpatient had any association with the prescription of SGLT2i in heart failure patients, along with the readmission rates and mortality reduction in a community setting. Methods We retrospectively collected data from a Community Hospital for 4 months from May 20 to September 20’2022 for patients admitted with heart failure. Data collection and analysis for 474 patients were done using Excel, the chi-square test, and Python algorithms. The eligibility for SGLT2i was defined as any patient with the diagnosis of Heart failure with GFR>30ml/min/1.73m2. Results Our results revealed that only 4%(19/474) of the patients eligible for SGLT2i were receiving the medication. Out of the list of 19 patients prescribed SGLT2i, it was a home medication for 16 and started in the Hospital for 3 patients. Out of the list of patients who were prescribed SGLT2i, 63%(12/19) had an inpatient cardiology consult and 57%(11/19) of patients had an outpatient cardiologist. 46.3%(211/455) of patients who were not on SGLT2i had been seen by a cardiologist inpatient but never on the medication. 25%(116/455) of patients who were not on the medication had an outpatient cardiologist. The chi-square test for outpatient cardiologist and inpatient cardiology consult revealed a p-value of 0.6 and 0.3 respectively. 100% of the patients on SGLT2i with GFR<30 and >45 had no readmission reported. 20% readmission rates were reported in patients with GFR 30-45 at <30 days. 0% mortality was reported in patients on SGLT2i with GFR< 30, in comparison to 0.4% in patients with GFR>45 and 1.6% in patients with GFR 30-45 and the study was statistically insignificant (p value-0.3). Conclusion We found no association to conclude that having an inpatient cardiology consult or follow-up with a cardiologist outpatient increases the chances of a patient with heart failure to be prescribed SGLT2i. The study does reproduce the reduction in readmission rates, hospitalization, and mortality rates as was demonstrated in large-scale trials confirming the utilization of this drug at a community level. The barriers associated with the nonprescription of the SGLT2i include the lack of awareness about its indications in both HFpEF and HFrEF, its contraindications, and the inconvenience associated with prescription in patients requiring prior authorization. Our Quality improvement project aimed at recognizing these barriers and introducing interventions including forming a dot phrase for documentation for patients admitted with the diagnosis of heart failure, initiating the prior authorization form if needed in the hospital.

Electronic Health Record Alert With Heart Failure Risk and Sodium Glucose Cotransporter 2 Inhibitor Prescriptions in Diabetes: A Randomized Clinical Trial

Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care with or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure

Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data

SGLT2i Prescribing Patterns Among Medically And Socially Complex Patients With Heart Failure Within An Urban Internal Medicine Teaching Clinic

Author Response for "effectiveness of Sodium‐glucose Co‐transporter‐2 Inhibitors on Ischemic Heart Diseases"

Real-world Use and Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Diabetes and Heart Failure: A Population-level Cohort Study in Alberta, Canada

1121-P: Effectiveness of Sodium–Glucose Cotransporter 2 Inhibitors on Coronary Heart Disease Compared with Other Glucose Lowering Drugs

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.

Uptake of sodium-glucose cotransporter-2 inhibitors in hospitalized patients with heart failure: insights from the veterans affairs healthcare system

Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems

GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors

Telehealth Intervention to Improve Uptake of Evidence-Based Medications among Patients with Type 2 Diabetes and Heart Failure or Cardiovascular Disease

Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice

Quality Improvement Project To Study The Role Of A Cardiologist In Prescription Of Sglt2 Inhibitors In Patients With Heart Failure

Implementation of sodium-glucose co-transporter 2 inhibitors in patients with heart failure through a new digital strategy (EMAIL-HF): a randomised clinical trial study design

A Real-world Study Evaluating the Clinical Factors Associated with the Initial SGLT2 Inhibitor Prescription

Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health record

Sodium-Glucose Cotransporter 2 Inhibitors in South Australia: The Magic Before the Fame

Unmasking patients insight into SGLT2 inhibitors- a collaborative quality improvement project to enhance patient education and safety

Natural Language Processing Extracted Social And Behavioral Determinants Of Health And Newer Glucose-lowering Drug Initiation Among Real-world Patients With Type 2 Diabetes